ProShares Ultra Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN · NET −$16M OVER THIS RANGE
Money keeps arriving — +$2M of net buying over the past month, about 1.5% of the fund's asset base, while the price has returned +53.4% so far this year. At 0.95% a year it is not the cheapest way in — IBRN runs the same ground at 0.47%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
| 1 week | +11.2% |
| 1 month | +24.8% |
| 3 months | +49.0% |
| 6 months | +39.8% |
| YTD | +53.4% |
| 1 year | +115.2% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$3M |
| 1 month | +$2M |
| 3 months | −$950K |
| YTD | −$16M |
| 1 year | −$10M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
Due diligence cuts both ways. These funds sit on the same shelf and beat BIB on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.03% | $97.9B | +$245M | -92bp on fee · 944× the assets · +$245M in over the month | Head-to-head |
| IUSG iShares Core S&P U.S. Growth ETF | 0.04% | $33.8B | +$668M | -91bp on fee · 326× the assets · +$668M in over the month | Head-to-head |
| IUSV iShares Core S&P U.S. Value ETF | 0.04% | $28.1B | +$103M | -91bp on fee · 271× the assets · +$103M in over the month | Head-to-head |
| IVV iShares Core S&P 500 ETF | 0.03% | $900.9B | −$14.2B | -92bp on fee · 8681× the assets | Head-to-head |
| VOO Vanguard 500 Index Fund | 0.03% | $500.4B | — | -92bp on fee · 4822× the assets | Head-to-head |